introduction
Point-of-care testing can be defined as pathology testing performed on-site during the patient consultation. It allows a rapid test result to be generated and used to make an immediate, informed clinical decision.
There have been significant technological and analytical advances in point-of-care testing devices and reagent manufacture. An increasing range of tests can now be performed on very small sample volumes in less than 10 minutes. These include tests for glucose, glycated haemoglobin (HbA1c), lipids, electrolytes, urea and creatinine, blood gases and coagulation and cardiac markers. The analytical performance of many point-of-care testing devices is equivalent to that of a laboratory and meets profession-derived analytical goals. 1, 2 
Clinical applications
Point-of-care tests (both singly and in profile) are now available for acute and chronic situations and can be used for example in managing diabetes, warfarin requirements, electrolyte and acid-base disturbances and risk stratification of patients with suspected acute coronary syndrome. 
Abnormal laboratory results

Glycaemic control
HbA1c remains the gold standard pathology test for long-term monitoring of glycaemic control in patients with diabetes. Devices measure HbA1c using either immunoassay or boronate affinity chromatography methods.
There are numerous strip-based testing devices for glucose monitoring. These generally measure whole blood glucose rather than plasma glucose, although newer devices can report a plasma-equivalent glucose concentration.
Blood lipids
Measuring blood lipids is useful for cardiovascular disease risk assessment and for managing patients on lipid lowering therapy.
Testing devices measure a full lipid profile on capillary or venous blood. However, they calculate the low density lipoprotein (LDL) cholesterol using the Friedewald formula and cannot, as yet, determine LDL cholesterol directly as laboratories can now do.
Assessing renal function
Quantitative measurement of urine albumin or urine albumincreatinine ratio is a key component in the review of patients with diabetes. Plasma creatinine measurement is currently the subject of an international standardisation, in which both laboratory and point-of-care testing methods are being aligned to an isotope dilution mass spectrometry reference method.
Warfarin monitoring
Point-of-care INR testing is becoming increasingly popular in general practice for monitoring patients on warfarin therapy. 3 Results can be linked with computer decision support software that automatically recommends the patient's next dose of warfarin.
Acute care
In an acute situation, electrolytes (including anion gap), blood gases and cardiac markers, notably troponin I or T, can be assessed. Some devices can measure these cardiac troponins down to the nanogram per mL range. Newer markers including brain natriuretic peptide (BNP) and N-terminal pro b-type natriuretic peptide (NT-proBNP) remain expensive and their clinical utility continues to be debated.
Point-of-care testing models
In Australia, point-of-care testing is being used in the community as well as in hospitals particularly in rural and remote areas where access to laboratory services may be poor. There are now a number of working examples of innovative community-based point-of-care testing models that have improved clinical outcomes in both chronic and acute situations and are analytically sound (see box).
Managing point-of-care testing
A systematic approach is needed to organise and manage a sustainable and clinically effective point-of-care testing service. 4 
Physical requirements
only a small area of dedicated bench space is required to conduct 
Analytical quality
A management system incorporating quality control and quality assurance processes adapted for non-laboratory settings is needed to continually ensure that the analytical quality of point-of-care testing results is appropriate for patient care. The capacity to sustain a point-of-care testing service in a remote health service setting is often limited by high rates of staff (device operator) turnover. 13 At present there is no Medicare rebate for point-of-care tests in general practice (other than a small group of mainly qualitative tests such as a pregnancy test). This limits the potential uptake of point-of-care technology and means a thorough cost-benefit analysis is needed before making the decision to implement point-of-care testing.
Conclusion
General practice and particularly rural and remote medical services are increasingly using point-of-care testing. To sustain a point-of-care testing service, it is important to have ongoing technical support from the manufacturer of the device.
Test results
A further recent technological advance has been the capacity to send results electronically from multiple point-of-care testing devices to a central management point and from there to a clinical or hospital information system. This improved connectivity has enhanced the ability to develop large-scale point-of-care testing networks and streamline the delivery of testing services. Many Australian diagnostic companies provide connectivity software for their testing devices.
is point-of-care testing effective?
There is a growing evidence base for the clinical, operational and economic effectiveness of point-of-care testing in hospitals and in the community.
Chronic care
For chronic care, there are published examples of how point-ofcare testing can be an effective tool for improving control of chronic conditions either by reductions in HbA1c (for diabetes management) 7 or increased time in therapeutic or target ranges (coagulation studies). 3
Acute care
The ability to perform tests such as potassium and blood gases by point-of-care testing in under five minutes on an acutely ill patient can inform initial management. For example, being able to measure potassium levels in a patient presenting with severe vomiting or diabetic ketoacidosis in a remote health centre is particularly useful.
Similarly, the ability to rapidly stratify risk in patients with suspected acute coronary syndrome using supportive cardiac marker pointof-care testing can have benefits. These relate to reduced length of stay in emergency departments or reduced mortality through more rapid and effective risk stratification and treatment. 8, 9 General practice A large randomised controlled trial of point-of-care testing in Australian general practice was commissioned by the Department of Health and Ageing. 10 As part of the trial, the effectiveness of point-of-care testing versus laboratory testing was assessed for managing chronic conditions in general practice. Data from 53 practices located in urban, rural and remote locations in Australia were analysed. Based on the primary outcome of percentage of patients with test results in the target range, point-of-care tests for HbA1c, urine albumin, albumin-creatinine ratio, total cholesterol and triglycerides were non-inferior to laboratory testing, but not for INR and HDL cholesterol. 11, 12 Limitations of point-of-care testing
While point-of-care testing may appear simple and easy to adopt, it is critical that health professionals seek the support of their local
